{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:57:47Z","timestamp":1793656667301,"version":"4.5.1"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>People living with heart failure (HF) with mildly reduced or preserved ejection fraction have substantially curtailed life expectancy free from clinical events compared with their peers of comparable age. The nonsteroidal mineralocorticoid receptor antagonist, finerenone, was recently shown to reduce risks of cardiovascular events in this population over a median follow-up of 2.6 years; as patients with HF typically continue treatment beyond this time frame, estimating the potential long-term benefits of finerenone could inform shared clinical decision-making.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To estimate the projected long-term treatment effects of finerenone in patients with HF with mildly reduced or preserved ejection fraction if treated over a patient\u2019s lifetime.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>Prespecified analyses were conducted of the FINEARTS-HF trial, a phase 3 randomized clinical trial conducted across 653 sites in 37 countries. Adults 40 years and older with symptomatic HF and left ventricular ejection fraction of 40% or greater were randomized from September 2020 to January 2023. Median (IQR) follow-up was 2.6 (1.9-3.0) years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Finerenone (titrated to either 20 mg or 40 mg) or placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary composite outcome was time to cardiovascular death or worsening HF event. The long-term gains in survival free from a primary end point with finerenone were iteratively estimated with age-based Kaplan-Meier curves using age at randomization rather than time from randomization. Differences in areas under the survival curves between the finerenone and placebo arms represented event-free survival gains.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 6001 participants (median [IQR] age, 73 [66-79] years; 3269 male [54.5%]), mean survival free from the primary end point for a 55-year-old participant was 13.6 years (95% CI, 11.9-15.2 years) with finerenone and 10.5 years (95% CI, 6.8-11.3 years) with placebo, representing a gain in event-free survival of 3.1 years (95% CI, 0.8-5.4 years; <jats:italic>P<\/jats:italic>\u2009=\u2009.007). Mean event-free survival for a 65-year-old participant was 11.0 years (95% CI, 10.1-11.9 years) with finerenone and 8.9 years (95% CI, 8.1-9.8 years) with placebo, representing a gain of 2.0 years (95% CI, 0.8-3.3 years; <jats:italic>P<\/jats:italic>\u2009=\u2009.001). Projected mean event-free survival was numerically greater with finerenone than with placebo for every starting age between 50 to 80 years. Lifetime gains in event-free survival were observed even among individuals already treated with a sodium-glucose cotransporter 2 inhibitor (65-year-old participant: 3.1 years; 95% CI, 0.1-6.0 years; <jats:italic>P<\/jats:italic>\u2009=\u2009.04).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this prespecified secondary analysis of the FINEARTS-HF randomized clinical trial, long-term treatment with finerenone was estimated to extend event-free survival by up to 3 years among people with HF with mildly reduced or preserved ejection fraction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04435626\">NCT04435626<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2024.3782","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T22:30:22Z","timestamp":1727476222000},"page":"176","source":"Crossref","is-referenced-by-count":24,"title":["Estimated Long-Term Benefits of Finerenone in Heart Failure"],"prefix":"10.1001","volume":"10","author":[{"given":"Muthiah","family":"Vaduganathan","sequence":"first","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[{"name":"University of Glasgow, Glasgow, Scotland, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S. P.","family":"Lam","sequence":"additional","affiliation":[{"name":"National Heart Centre Singapore & Duke-National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Senni","sequence":"additional","affiliation":[{"name":"University of Milano-Bicocca ASST Papa Giovanni XXIII Hospital, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv J.","family":"Shah","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[{"name":"University of Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"University of Lorraine, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Borentian","sequence":"additional","affiliation":[{"name":"Bayer, Research & Development, Pharmaceuticals, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lay-Flurrie","sequence":"additional","affiliation":[{"name":"Bayer, Research & Development, Pharmaceuticals, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhakar","family":"Viswanathan","sequence":"additional","affiliation":[{"name":"Bayer, Research & Development, Pharmaceuticals, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike U.","family":"Behmenburg","sequence":"additional","affiliation":[{"name":"Bayer, Research & Development, Pharmaceuticals, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"University of Glasgow, Glasgow, Scotland, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"20","key":"hbr240014r1","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart Failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes.","volume":"70","author":"Shah","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"10354","key":"hbr240014r2","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of 5 randomized controlled trials.","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"issue":"37","key":"hbr240014r3","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"issue":"17","key":"hbr240014r4","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines.","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"hbr240014r5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction.","author":"Solomon","journal-title":"N Engl J Med"},{"issue":"10166","key":"hbr240014r6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","article-title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomized trial.","volume":"393","author":"Halliday","year":"2019","journal-title":"Lancet"},{"issue":"23","key":"hbr240014r7","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1056\/NEJMc1509753","article-title":"Estimating the long-term treatment benefits of sacubitril-valsartan.","volume":"373","author":"Claggett","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"hbr240014r8","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/ejhf.3253","article-title":"Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: rationale and design of the FINEARTS-HF trial.","volume":"26","author":"Vaduganathan","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"hbr240014r9","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/ejhf.3266","article-title":"Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: the FINEARTS-HF trial.","volume":"26","author":"Solomon","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"hbr240014r10","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.1002\/ehf2.13731","article-title":"Within trial comparison of survival time projections from short-term follow-up with long-term follow-up findings.","volume":"9","author":"Ferreira","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"11","key":"hbr240014r11","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1001\/jamacardio.2021.2632","article-title":"Extrapolating long-term event-free and overall survival with dapagliflozin in patients with heart failure and reduced ejection fraction: an exploratory analysis of a phase 3 randomized clinical trial.","volume":"6","author":"Docherty","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"10244","key":"hbr240014r12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of 3 randomized controlled trials.","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"issue":"12","key":"hbr240014r13","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.jchf.2020.08.004","article-title":"Estimating the lifetime benefits of treatments for heart failure.","volume":"8","author":"Ferreira","year":"2020","journal-title":"JACC Heart Fail"},{"issue":"18","key":"hbr240014r14","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1016\/j.jacc.2019.02.043","article-title":"Estimated long-term survival with eplerenone.","volume":"73","author":"Stienen","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"hbr240014r15","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/j.jacc.2022.08.745","article-title":"Estimated long-term benefit of dapagliflozin in patients with heart failure.","volume":"80","author":"Vaduganathan","year":"2022","journal-title":"J Am Coll Cardiol"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2824342\/jamacardiology_vaduganathan_2024_br_240014_1738111911.28785.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T16:02:04Z","timestamp":1739376124000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2824342"}},"subtitle":["A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2024.3782","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,1]]}}}